Prostate Cancer Marketplace Discussed & Forecast in FirstWord Report Available at

26 Feb 2016 • by Natalie Aster

LONDON – In the USA alone, there were around 221,000 new cases of prostate cancer were registered in 2015. Besides, there were approximately 27,540 deaths from prostate cancer in the country. Prostate cancer is one of two major causes of cancer deaths in American men, with lung cancer being the leader.

A number of significant changes have taken place in the field of prostate cancer treatment over the last ten years. For instance, a new gold standard of care has sprung out given results received from several trials that have been carried out recently. Besides, some drugs are expected to move up the treatment paradigm in the years to come.

In the meantime, the marketplace is becoming increasingly competitive, and some brands make steps to deepen their footprint in undertreated populations.

Cutting-edge research report “Prostate Cancer: KOL Insight” drawn up by FirstWord offers an up-close look at the prostate cancer treatment space. The study provides an insightful overview of this marketplace. It delves deep into impact that STAMPEDE and CHAARTED trials have on the existing treatment paradigm. The report comprises a detailed overview of marketed drugs. The research study explores bone-targeted therapies and sheds light on immunotherapies. It also discusses other new therapies and contains KOLs insights.

Report Details:

Prostate Cancer: KOL Insight
Published: November, 2015
Price: US$ 7,495.00

Report Highlights:

  • all-round overview of the marketplace;
  • identification of remaining unmet needs (on the basis of patient population);
  • details on differences existing in current and evolving treatment choices for non-metastatic and metastatic disease;
  • information on factors impacting the combination therapies’ choice;
  • KOLs’ opinions;
  • and more.

More new research studies by our market research partner can be found at FirstWord page


The Market Publishers, Ltd.
Natalie Aster
Tel: +44 208 144 6009
Fax: +44 207 900 3970